These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 16893698)

  • 21. Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size.
    Regar E; Serruys PW; Bode C; Holubarsch C; Guermonprez JL; Wijns W; Bartorelli A; Constantini C; Degertekin M; Tanabe K; Disco C; Wuelfert E; Morice MC;
    Circulation; 2002 Oct; 106(15):1949-56. PubMed ID: 12370218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
    Kereiakes DJ; Sudhir K; Hermiller JB; Gordon PC; Ferguson J; Yaqub M; Sood P; Su X; Yakubov S; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1229-39. PubMed ID: 21232716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of everolimus-eluting stent with a bioresorbable polymer coating for treatment of recurrent in-stent restenosis.
    Honda H; Meguro T; Takizawa K; Isoyama S
    J Invasive Cardiol; 2005 Feb; 17(2):112-5. PubMed ID: 15687539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Everolimus-eluting stents compared with paclitaxel-eluting stents for treatment of coronary in-stent restenoses.
    Markovic S; Paliskyte R; Rottbauer W; Wöhrle J
    Cardiovasc Revasc Med; 2012; 13(6):307-10. PubMed ID: 23164475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Percutaneous coronary revascularization using a trilayer metal phosphorylcholine-coated zotarolimus-eluting stent.
    Abizaid A; Lansky AJ; Fitzgerald PJ; Tanajura LF; Feres F; Staico R; Mattos L; Abizaid A; Chaves A; Centemero M; Sousa AG; Sousa JE; Zaugg MJ; Schwartz LB
    Am J Cardiol; 2007 May; 99(10):1403-8. PubMed ID: 17493469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
    Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B
    Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial.
    Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Bruining N; Van den Branden F; Van Langenhove G
    J Am Coll Cardiol; 2006 Dec; 48(12):2423-31. PubMed ID: 17174178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initial and late efficacy of everolimus-eluting stents for small and non-small coronary lesions from evaluating delayed late loss study.
    Tama N; Uzui H; Horita Y; Namura M; Tada H
    Heart Vessels; 2017 Dec; 32(12):1415-1423. PubMed ID: 28687988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IMPACT Trial: angiographic and intravascular ultrasound observations of the first human experience with mycophenolic acid-eluting polymer stent system.
    Abizaid A; Albertal M; Ormiston J; Londero H; Ruygrok P; Seixas AC; Feres F; Mattos LA; Staico R; Silva RL; Webster M; Stewart J; Paoletti F; Kataoka T; Fitzgerald P; Sousa A; Sousa JE
    Catheter Cardiovasc Interv; 2005 Dec; 66(4):491-5. PubMed ID: 16283680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Experimental evaluation of efficacy and healing response of everolimus-eluting stents in the familial hypercholesterolemic swine model: a comparative study of bioabsorbable versus durable polymer stent platforms.
    Tellez A; Seifert PS; Donskoy E; Sushkova N; Pennington DE; Milewski K; Krueger CG; Kaluza GL; Eppihimer MJ; Huibregtse BA; Dawkins KD; Granada JF
    Coron Artery Dis; 2014 May; 25(3):198-207. PubMed ID: 24642807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pilot study with an intensified oral sirolimus regimen for the prevention of in-stent restenosis in de novo lesions: a serial intravascular ultrasound study.
    Chaves AJ; Sousa AG; Mattos LA; Abizaid A; Feres F; Staico R; Centemero M; Tanajura LF; Abizaid AC; Rodrigues A; Paes A; Mintz GS; Sousa JE
    Catheter Cardiovasc Interv; 2005 Dec; 66(4):535-40. PubMed ID: 16283682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of sirolimus-eluting stent in diabetic patients with small coronary arteries (a SES-SMART substudy).
    Ortolani P; Ardissino D; Cavallini C; Bramucci E; Indolfi C; Aquilina M; Marzocchi A
    Am J Cardiol; 2005 Nov; 96(10):1393-8. PubMed ID: 16275185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome after acute incomplete sirolimus-eluting stent apposition as assessed by serial intravascular ultrasound.
    Kimura M; Mintz GS; Carlier S; Takebayashi H; Fujii K; Sano K; Yasuda T; Costa RA; Costa JR; Quen J; Tanaka K; Lui J; Weisz G; Moussa I; Dangas G; Mehran R; Lansky AJ; Kreps EM; Collins M; Stone GW; Moses JW; Leon MB
    Am J Cardiol; 2006 Aug; 98(4):436-42. PubMed ID: 16893693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Late restenosis following placement of a sirolimus eluting stent for in-stent restenosis.
    Ali OA; Lowe H; Kritharides L; Brieger D
    Heart Lung Circ; 2007 Feb; 16(1):50-1. PubMed ID: 17196881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immediate and long-term outcomes of drug-eluting stent implantation for unprotected left main coronary artery disease: comparison with bare-metal stent implantation.
    Gao RL; Xu B; Chen JL; Yang YJ; Qiao SB; Li JJ; Qin XW; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J
    Am Heart J; 2008 Mar; 155(3):553-61. PubMed ID: 18294496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiographic results of the first human experience with the Biolimus A9 drug-eluting stent for de novo coronary lesions.
    Costa RA; Lansky AJ; Abizaid A; Müeller R; Tsuchiya Y; Mori K; Cristea E; Leon MB; Sousa JE; Schmidt T; Hauptmann KE; Grube E
    Am J Cardiol; 2006 Aug; 98(4):443-6. PubMed ID: 16893694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of intravascular ultrasound lesion characteristics on neointimal hyperplasia following sirolimus-eluting stent implantation.
    Kaneda H; Koizumi T; Ako J; Terashima M; Morino Y; Honda Y; Yock PG; Leon MB; Moses JW; Fitzgerald PJ
    Am J Cardiol; 2005 Nov; 96(9):1237-41. PubMed ID: 16253589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term safety and efficacy of second-generation everolimus-eluting stents compared to other limus-eluting stents and bare metal stents in patients with acute coronary syndrome.
    Omar A; Torguson R; Kitabata H; Pendyala LK; Loh JP; Magalhaes MA; Satler LF; Suddath WO; Pichard AD; Waksman R
    Catheter Cardiovasc Interv; 2014 Dec; 84(7):1053-60. PubMed ID: 24619969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.